Intraoperative Tumor Margin Identification With ICG Dye Imaging

Recruiting Phase 2 Interventional Study
Benign Neoplasm Malignant Neoplasm
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Diagnostic
Participants needed
100 (estimated)
Sponsor
Massachusetts General Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
In this research study we want to learn more about the use of indocyanine green (ICG) during bone or soft tissue mass resections. Indocyanine green (ICG) is a type of dye that is used in medical diagnostics. We want to determine if ICG-guided tumor resection is more effective in obtaining negative margins. Lastly, we want to assess traditional oncologic outcomes of local recurrence, time to metast…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * All patients 18 years of age or older who present to Massachusetts General Hospital Department of Orthopaedic Surgery with a benign or malignant bone or soft tissue mass that is consented for surgery during the study period. Exclusion Criteria: * Pregnant or nursing patients…
Contacts

Santiago A Lozano-Calderon, MD, PhD

(617) 643-4947

SLOZANOCALDERON@mgh.harvard.edu

CONTACT

Shreya Halur, BS

(617) 726-4932

shalur@mgh.harvard.edu

CONTACT